


- Prognostic Risk: The ArteraAl prognostic risk group can explain how aggressive the patient's prostate cancer is. The 10-year risk of distant metastasis is reported as a continuous variable with low-, intermediate-, and high-risk categories.
- **Additional Prognostic Endpoints:** In addition to the 10-year risk of distant metastasis, 10-year risk of prostate cancer-specific mortality is also reported. This can help provide more information to support optimized decision-making.
- Active Surveillance Insights: For men with NCCN very low-, low-, and favorable intermediate-risk prostate cancer, comparing their risk of adverse pathology to that of other patients who were on active surveillance (AS) and underwent radical prostatectomy can help determine if AS is a suitable management option.



Comparison With National Comprehensive Cancer Network (NCCN) Risk Group: There is variability among patients within NCCN risk groups. A visualization is provided to show how the risk of metastasis, based on the ArteraAl risk score, compares to other patients with NCCN low/very low-risk disease.